pentobarbital will minimize the extent or outcome of nisoldipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will reduce the level or effect of repaglinide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will minimize the extent or outcome of quinine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unfamiliar.
pentobarbital will lower the extent or effect of bosentan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.
pentobarbital will decrease the extent or impact of brexpiprazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Closely. Double brexpiprazole dose over 1-two months if administered with a strong CYP3A4 inducer.
pentobarbital will minimize the extent or effect of quetiapine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
Avoid; coadministration with CYP3A inducers may well cause decreased plasma concentrations of elvitegravir and/or possibly a click here concomitantly administered protease inhibitor and result in loss of therapeutic impact and to feasible resistance
pentobarbital will lower the level or influence of dasatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will minimize the level or impact of eltrombopag by influencing hepatic enzyme CYP2C9/ten metabolism. Use Warning/Watch.
pentobarbital will lessen the extent or influence of mavacamten by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will lower the level or effect of alfentanil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.
pentobarbital will decrease the extent or result of buprenorphine, long-performing injection by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Sufferers who transfer to buprenorphine very long-acting injection from transmucosal buprenorphine coadministered with CYP3A4 inducers needs to be monitored to be sure buprenorphine plasma stages are adequate.
pentobarbital will decrease the level or influence of dienogest/estradiol valerate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Gals should not decide on estradiol valerate/dienogest as their contraceptive although utilizing strong CYP3A4 inducers because of potential lessen in contraceptive efficacy.
pentobarbital will minimize the level or outcome of fostemsavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.